The incidence rate is highest with combination therapy and lowest with CTLA-4 inhibitors (5, 6, 24), This suggests that differences in the mechanism of action of ICIs are associated with the varied incidence of ICI-induced thyroiditis. This evidence concerns the gene CTLA4 and thyroid gland disorder.